Document is current

Article History

Received: 25 September 2024

Accepted: 23 December 2024

First Online: 11 January 2025

Competing interests

: D.J.B. has the following disclosures: Consulting or Advisory Role: AIMED BIO, Astellas, AVEO Oncology, Bayer, Eisai, EMD Serono, Exelixis, Janssen, Seagen. Speakers’ Bureau: Merck. Travel and Accommodations: DAVA Oncology, Merck, Seagen. T.T.A. has the following disclosure: Employment: Caris Life Sciences. A.E. has the following disclosure: Employment: Caris Life Sciences. S.D. has the following disclosures: Consulting Role: BostonGene. T.L. declares no conflict of interest. R.R.M. has the following disclosures: advisory board and or consulting fees from AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Eli Lilly, Eisai, Exelixis, Janssen, Merck, Myovant, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus; and research support from AstraZeneca, Artera, Bayer, Bristol-Myers Squibb, Exelixis, Oncternal, and Tempus. M.J.O. has the following disclosure: Employment: Caris Life Science. A.R.K. has the following disclosures: Stock and Other Ownership Interests: ECOM Medical. Consulting or Advisory Role: AIMED BIO, Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics, Gilead Sciences. Speakers’ Bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences, AVEO. Research Funding: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics, Epizyme. Travel, Accommodations, Expenses: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis, AstraZeneca.